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Abstract
Background: Clinical checklists available have been developed to assess the risk
of a positive Fragile X syndrome but they include relatively small sample sizes.
Therefore, we carried out a meta-analysis that included statistical pooling of study
results to obtain accurate figures on the prevalence of clinical predictors of Fragile
X syndrome among patients with intellectual disability, thereby helping health
professionals to improve their referrals for Fragile X testing.
Methods: All published studies consisting of cytogenetic and/or molecular screening
for fragile X syndrome among patients with intellectual disability, were eligible for the
meta-analysis. All patients enrolled in clinical checklists trials of Fragile X syndrome
were eligible for this review, with no exclusion based on ethnicity or age. Odds ratio
values, with 95% confidence intervals as well as Cronbach coefficient alpha, was
reported to assess the frequency of clinical characteristics in subjects with intellectual
disability with and without the fragile X mutation to determine the most discriminating.
Results: The following features were strongly associated with Fragile X syndrome:
skin soft and velvety on the palms with redundancy of skin on the dorsum of hand
[OR: 16.85 (95% CI 10.4–27.3; a:0.97)], large testes [OR: 7.14 (95% CI 5.53–9.22; a:
0.80)], large and prominent ears [OR: 18.62 (95% CI 14.38–24.1; a: 0.98)], pale blue
eyes [OR: 8.97 (95% CI 4.75–16.97; a: 0.83)], family history of intellectual disability
[OR: 3.43 (95% CI 2.76–4.27; a: 0.81)] as well as autistic-like behavior [OR: 3.08
(95% CI 2.48–3.83; a: 0.77)], Flat feet [OR: 11.53 (95% CI 6.79–19.56; a:0.91)], plan-
tar crease [OR: 3.74 (95% CI 2.67–5.24; a: 0.70)]. We noted a weaker positive associa-
tion between transverse palmar crease [OR: 2.68 (95% CI 1.70–4.18; a: 0.51)],
elongated face [OR: 3.69 (95% CI 2.84–4.81; a: 0.63)]; hyperextensible metacarpo-
phalangeal joints [OR: 2.68 (95% CI 2.15–3.34; a: 0.57)] and the Fragile X syndrome.
Conclusion: This study has identified the highest risk features for patients with
Fragile X syndrome that have been used to design a universal clinical checklist.
KEYWORD S
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1 | INTRODUCTION
Fragile X Syndrome (FXS) is the most common known
inherited form of intellectual disability and has been reported
as the most common known inherited single-gene disorder
associated with autism spectrum disorder (ASD), accounting
for 2%–3% of all cases of ASD (Sherman et al., 1985). Stud-
ies estimate the prevalence of FXS to be 1 in 4,000 to 1 in
7,000 in males and 1 in 6,000 to 1 in 11,000 in females
(Crawford et al., 2002). In 99% of patients, the molecular
basis of the FXS is an expanded CGG repeat string (>200
hyper methylated CGG repeats, full mutation) in the 50
untranslated region of the FMR1 gene located at Xq27.3.
Since the identification of FXS as a major cause of intellec-
tual disability (ID), extensive screening programs have been
developed and carried out to identify patients in many coun-
tries. To increase the efficiency of the screening programs,
about 10 clinical checklists have been developed for prese-
lection of subjects based on clinical features. The use of
checklists to select patients with a high probability of being
affected by FXS may significantly reduce the number of
individuals to be submitted to molecular evaluation (Mandel
& Chelly, 2004), greatly improving the cost-effectiveness of
Fragile X testing. Such clinical checklists have been devel-
oped in different populations with different ethnic back-
grounds such as Caucasians, African Americans, Latinos,
Indians, and Chinese (Butler, Mangrum, Gupta, & Singh,
1991; Giangreco, Steele, Aston, Cummins, & Wenger, 1996;
Guo et al., 2000; Hagerman, Amiri, & Cronister, 1991;
Laing, Partington, Robinson, & Turner, 1991; Limprasert
et al., 2000; Maes, Fryns, Ghesquiere, & Borghgraef, 2000).
In our recent paper, we shown that facial dysmorphism
is influenced by ethnic background of the patient (Lumaka
et al., 2017). Moreover, clinical available checklists have
been developed in relatively small sample sizes, increasing
the chance of assuming as true a false hypothesis. There-
fore, we carried out a meta-analysis that included statistical
pooling of study results to obtain accurate figures on the
prevalence of clinical predictors of FXS among patients
with ID. This meta-analysis also aims to assess variations
in prevalence of clinical features among patients from dif-
ferent ethnic backgrounds, thereby helping to develop a
universal clinical checklist to improve their referrals for
Fragile X testing.
2 | MATERIALS AND METHODS
2.1 | Assessment of studies for inclusion in
this review
Two coauthors independently conducted a systematic
review of previous published studies for inclusion in the
present work. Included studies were assessed based on trial
quality. Data were extracted independently, and a meta-
analysis was performed after transforming reported data
using the intention-to screen principle. This review used
standard methods proposed by the Cochrane Collaboration
(van Tulder, Furlan, Bombardier, & Bouter, 2003).
2.2 | Types of studies
All published studies consisting of cytogenetic and/or molec-
ular screening for fragile X syndrome among patients with
intellectual disability, were eligible for the meta-analysis.
2.3 | Types of participants
All patients enrolled in clinical checklists studies of FXS
were eligible for this review, with no exclusion based on
ethnicity or age.
2.4 | Search strategy for identification of
studies
Electronic searches of the specific journals and technical
reports were performed.
2.5 | Methods of the review
Two authors independently selected studies for possible inclu-
sion against a predetermined checklist of inclusion criteria.
We searched in PubMed and Google Scholar from Jan-
uary 1991 to December 2016 for articles in English, Ger-
man, French, Spanish, Portuguese and Chinese. Following
keywords/terms were searched: Fragile X syndrome*,
checklist*, screening*, signs*, and diagnosis*. An asterisk
after a term means that all terms that begin with that root
were included in the search.
2.5.1 | Step 1
Abstracts were reviewed by the first author (TL) and
selected for further review if they met one of the following
two criteria: (1) Significant studies that covered Fragile X
syndrome clinical features (2) Clinical checklists for FXS
screening. If a criterion was not met because not enough
information was provided, the abstract was set aside for
further evaluation.
2.5.2 | Step 2
Abstracts were reviewed independently by two authors (TL
and GK) and were selected based on their consensus
according to the same criteria used in Step 1. If consensus
was not reached, the abstract was then set aside for further
evaluation.
LUBALA ET AL. | 527
2.5.3 | Step 3
Full-text articles of abstracts selected in Step 2 were
retrieved and reviewed by one author (TL). Inclusion was
based on consensus between two investigators (TL and
GK). Disagreements were discussed with a third author
(OL). Studies were included if they met the following crite-
ria: (1) Clinical checklists development studies and (2)
diagnosis based on molecular analysis of the Fragile X
mutation. The exclusion criteria were (1) studies that did
not report confidence intervals (CI) or standard errors (SE)
and that (2) did not report data that allowed the calculation
of these parameters and whose authors did not provide
such data upon request.
2.6 | Assessment of quality
Two authors independently assessed the susceptibility to
bias of the selected articles. The risk of bias was assessed by
reporting the study’s conduct against the criteria described
in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (van Tulder et al., 2003). Studies were categorized
as attributing a ‘low’, ‘moderate’, or ‘high’ risk of bias.
2.7 | Data extraction
Data were independently extracted by two coauthors using
a standard data extraction form. We extracted the following
data from each study: region(s) in which the study was con-
ducted, age group, gender, ethnicity of study sample, year
when the study was conducted, and dysmorphic features as
well as behavioral phenotype such as Autistic-like behavior
(Tactile defensiveness, perseverative speech, hand flapping,
poor eye contact) and attention-deficit hyperactivity disor-
ders (ADHD) in subjects with ID with and without the
Fragile X mutation. We classified region(s) in which the
study was conducted according to the United Nations’ clas-
sification of macro-geographic continental regions, namely,
Asia, Africa, Europe, North America, Latin America and
the Caribbean, and Oceania. Disagreements between coau-
thors were rare. In the event of a disagreement the data
were reviewed and resolved by discussion by three authors.
2.8 | Statistical analysis
Odds ratio (OR) values, with 95% confidence intervals (CI),
were reported to assess the frequency of clinical characteris-
tics in subjects with ID with and without the Fragile X muta-
tion to determine the most discriminating. Between-study
heterogeneity was estimated using the v2-based Q statistic.
Heterogeneity was considered statistically significant when
pheterogeneity <0.1. A statistical test with a p-value less than
.05 was considered significant. All analyses were performed
with RevMan software (version 5.1 for Windows, The
Cochrane Collaboration, Copenhagen, Denmark). A random-
effect meta-analyses model have been chosen to assume that
the observed clinical feature prevalence can vary across stud-
ies because of differences in study populations (age, ethnic-
ity). To confirm the associations found in the meta-analysis,
we used the reliability test by calculating the Cronbach coef-
ficient. Found factors with values between 0.91 and 1.0 gave
a strong association with FXS and those with values between
0.70 and 0.90 showed a good association.
The X-fragile diagnosis score is calculated using an
index built from the patient’s signs. (See the table above).
The index is built as follows:
• Each sign is rated 1 or 2.
• The score obtained are standardized according to a nor-
mal standardized distribution. Mean = 0; standard devia-
tion = 1.
• We attribute to each patient a final score which result
from the sum of the ratings of each sign present.
• Each patient is classified according to the score obtained.
The interpretation of the score (Min = 1, Max = 10).
≥5: X-fragile diagnosis is certain.
<5: X-fragile diagnosis is negative.
3 | RESULTS
Of the initial 8,140 records, two reviewers determined
independently that 16 required a full review of the manu-
script. The selection process of studies for inclusion in the
meta-analysis is shown in Figure 1. Six studies have been
excluded after the second and the third pass (Giangreco
et al., 1996; Guo et al., 2000; Limprasert et al., 2000;
Maes et al., 2000; Settin, Al-Haggar, Al-Baz, Al-Aiouty, &
Hafez, 2005). Our final primary analysis included 10 arti-
cles and the findings are summarized below in the tables.
All papers used in our analysis were published in English,
except for one that was written in Portuguese.
Table 1 summarizes the characteristics of included stud-
ies. It shows that six studies were from North America and
Europe (Arvio, Peippo, & Simola, 1997; Bellavance &
Morin, 2017; Butler, Brunschwig, Miller, & Hagerman,
1992; Hagerman et al., 1991; Lachiewicz, Dawson, & Spir-
idigliozzi, 2000; de Vries, Halley, Oostra, & Niermeijer,
1998), two from South to Central Asia (Guruju et al.,
2009; Kanwal et al., 2015), two from Latin America and
the Caribbean (Boy, Correia, Llerena, Machado-Ferreira, &
Pimentel, 2001; Christofolini et al., 2009), and one from
Africa (Behery, 2008). We did come across two interesting
fragile X syndrome studies from Sub-Saharan Africa, but
none of them met the criteria to be included in this study
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(Essop & Krause, 2013; Peprah, Allen, Williams, Woodard,
& Sherman, 2010). One American cohort was multiethnic,
including African-American patients.
Table 2 shows the results of meta-analyses of Clinical
features in Fragile X positive and in Fragile X negative
patients. Skin soft and velvety on the palms with redundancy
of skin on the dorsum of hand [Odds ratio: 16.85 (95% CI
10.4–27.3; a:0.97)], large testes [Odds ratio: 7.14 (95% CI
5.53–9.22; a: 0.80)], large and prominent ears [Odds ratio:
18.62 (95% CI 14.38–24.1; a: 0.98)], pale blue eyes [Odds
ratio: 8.97 (95% CI 4.75–16.97; a: 0.83)], family history of
intellectual disability [Odds ratio: 3.43 (95% CI 2.76–4.27;
a: 0.81)] as well as autistic-like behavior [Odds ratio: 3.08
(95% CI 2.48–3.83; a: 0.77)], flat feet [Odds ratio: 11.53
(95% CI 6.79–19.56; a:0.91)], plantar crease [Odds ratio:
3.74 (95% CI 2.67–5.24; a: 0.70)] were strongly associated
with the fragile X syndrome. We noted a weaker positive
association between Transverse palmar crease [Odds ratio:
2.68 (95% CI 1.70–4.18; a: 0, 51)], Elongated face [Odds
ratio: 3.69 (95% CI 2.84–4.81; a: 0.63)]; hyperextensible
metacarpo-phalangeal joints [Odds ratio: 2.68 (95% CI 2.15–
3.34; a: 0.57)] and the fragile X syndrome.
We propose in Table 3 a new checklist with the seven
most significant characteristics based on the findings shows
on Table 2.
4 | DISCUSSION
Here, we have reviewed in detail 10 articles that had con-
trolled and pertinent data for use in screening populations
of individuals with ID or ASD to determine who should
receive DNA testing for FXS. Such checklists are impor-
tant in areas where not everyone with ID or ASD can
undergo testing because of limited resources. This analysis
has revealed a group of characteristics that could be
FIGURE 1 Flow diagram of search strategy and study selection
TABLE 1 Baseline characteristics for studies included in meta-analysis
Study Year
Sample size n (%)
Age (Mean)
Gender
ratio (M:F)
Method for
Genetic diagnosis
of FXS
Population
ethnicityn X Fra + X Fra  p
Buttler et al. 1991 188 19 (10.1) 169 (89.9) ˂.001 3.7-71.9 (21.3) 1:0 CG North America
(USA)
Hagerman et al. 1991 106 15 (14.2) 91 (85.8) ˂.001 1-58 (30  5) 1:0 CG North America
(USA)
Arvio et al. 1997 370 26 (7.0) 344 (93.0) ˂.001 21-54 (31.7  11) 1:0 CG Europ (Finland)
De Vries et al. 1998 896 9 (1.0) 887 (99.1) ˂.001 NA (NA) 1:0 PCR (SB) Europ
(Netherland)
Lachiewizc et al. 2000 73 36 (49.3) 37 (50.7) .99 NA (6.2  2.4) 1:0 CG, DNA North America
(USA)
Boy et al. 2001 92 14 (15.2) 78 (84.8) ˂.001 7-27 (13.4) 5:1 CG Latin America
and the
Caribbean
(Brazil)
Behery 2008 200 34 (17.0) 166 (83.0) ˂.001 2–20 (NA) 1:0 RT-PCR Africa (Egypt)
Christofolini et al. 2009 192 30 (15.6) 162 (84.4) ˂.001 2–31 (11.3  5.6) 1:0 PCR (SB) Latin America
and the
Caribbean
(Brazil)
Guruju et al. 2009 327 25 (7.7) 302 (92.3) ˂.001 4–16 (NA) 1:0 PCR (SB) Asia (India)
Kanwal et al. 2015 357 13 (3.6) 344 (96.4) ˂.001 4–40 (14.28  7.01) 7:3 PCR (SB) Asia (Pakistan)
CG, Cytogenetics; SB, Southern Blot; RT-PCR, Real time Polymerase Chain Reaction.
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included in universal screening for FXS. As shown in
Table 2, the most discriminating items include large or
prominent ears, flat feet and soft velvet like skin and plan-
tar creases. All these features relate to the connective tissue
problems involving elastin (poorly developed, disorganized,
demonstrating a lack of the elastin tree-like structure in the
dermis) that are present in individuals with FXS (Davids,
Hagerman, & Eilert, 1990).
We have identified that the blue eyes are related to
FXS. However, this feature is associated with the ethnic
background. Even for Caucasians, it just reflects the ethnic
bias of about two studies and therefore would be inappro-
priate for a universal checklist.
Macroorchidism is related to the age and gender of the
patient. Therefore, for prepubertal or female children, this
item is less appropriate. If pubertal or older male patients
are included in the screening, then the growth abnormalities
leading to macroorchidism is a helpful feature for clinically
identifying those with FXS.
Although some autistic features are more common than
others, hand flapping, hand biting, and poor eye contact
are seen in the majority of subjects with FXS (Hagerman
et al., 1991). For simplification purpose, autistic-like
behaviors have been grouped. This feature is scored as pos-
itive when one of the following behaviors is present: tactile
defensiveness, hand flapping, hand biting, delayed or perse-
verative speech, and poor eye contact.
TABLE 2 Pooled prevalence and Odds ratio of Physical, Behavioral, and cognitive traits in patients with intellectual disability with and
without fragile X syndrome
Traits X Frag + X Frag 
Odds ratio
random (IC95%)
Heterogeneity
Test for
overall effect
Cronbach
Coeff.
v2 df (p) I2 z p a
Elongated face 109/151 533/2728 3.69 (2.84-4.81) 638.6 18 (˂.001) 45 103.9 ˂.001 0.63
Hyperextensible
metacarpo-phalangeal joints
150/220 849/3336 2.68 (2.15-3.34) 492.6 24 (˂.001) 37 80.3 ˂.001 0.57
Skin soft and velvety 38/43 95/1811 16.85 (10.4-27.3) 512.8 3 (˂.001) 57 212.1 ˂.001 0.97
Flat feets 26/37 43/115 11.53 (6.79-19.56) 46.4 3 (.001) 41 3.5 .061 0.91
Transverse palmarcrease/sydney lines 30/115 104/1064 2.68 (1.70-4.18) 45.2 12 (.012) 18 18.3 ˂.001 0.51
Plantar crease 84/98 162/707 3.74 (2.67-5.24) 232.8 9 (.001) 42 62.0 ˂.001 0.70
Large and prominent ears 173/206 756/3458 18.62 (14.38-24.1) 604.3 24 (.001) 39 163.7 ˂.001 0.98
Large testicles 129/181 291/2915 7.14 (5.53-9.22) 290.5 18 (.001) 33 281.4 ˂.001 0.80
Pale blue eyes 28/49 23/317 8.97 (4.75-16.97) 23.6 3 (.002) 24 48.5 ˂.001 0.83
Tactilely defensive 108/166 626/3274 3.40 (2.63-4.40) 957.7 24 (.012) 48 94.8 ˂.001 0.68
Hand flapping 75/128 404/1391 2.91 (2.20-3.84) 226.8 15 (.025) 32 20.1 ˂.001 0.59
Hand-biting 45/115 218/1062 1.91 (1.31-2.77) 84.3 12 (.256) 23 11.0 .001 0.39
Perseverative speech 107/161 675/1466 1.44 (1.11-1.87) 179.3 15 (.298) 29 7.3 .007 0.31
Poor eye contact 139/161 517/1506 2.51 (1.96-3.22) 361.4 21 (.012) 37 54.6 ˂.001 0.45
Hyperactivity 120/162 829/1576 1.41 (1.10-1.81) 372.2 18 (.001) 35 6.9 .009 0.41
Familial history of
intellectual disability
166/205 807/3418 3.43 (2.76-4.27) 584.6 24 (˂.001) 84 19.4 ˂.001 0.81
Short attention 91/115 511/1063 1.65 (1.23-2.21) 219.0 12 (.458) 33 10.6 .001 0.23
ADHD 122/162 870/1576 1.36 (1.06-1.75) 510.1 18 (.001) 41 5.7 .017 0.48
Autist Like Behaviora 162/213 854/3457 3.08 (2.48-3.83) 556.4 30 (˂.001) 79 75.6 ˂.001 0.77
aTactile defensiveness, perseverative speech, hand flapping, and poor eye contact.
TABLE 3 Clinical scoring for the seven most discriminant fragile
X features
Traits
Score
1 2
Skin soft and velvety on the palms with
redundancy of skin on the dorsum of hand
X
Flat feet X
Large and prominent ears X
Plantar crease X
Large testiclesa X
Familial history of ID X
Autistic-Like Behavior X
Total 4 6
aPostpubertal males only.
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Also important is a family history of ID or ASD since
FXS represents about 30% of the causes of X-linked ID and,
in most cases, there is a family history. The clinician can also
ask about a family history of premutation problems such as
early menopause, because the Fragile X-associated primary
ovarian insufficiency (FXPOI) occurs in about 20% of the
carriers, or a history of tremor, ataxia, or cognitive decline,
because the Fragile X-associated tremor ataxia (FXTAS) can
occur in about 50% of older male carriers and 16% of older
female carriers (Hagerman & Hagerman, 2013).
The main goal for our study was to develop a universal
and simplified clinical checklist for FXS screening among
subjects with ID based on the results of a meta-analysis of
previous screening studies. In the light of our results, we
propose a clinical FXS checklist for any population com-
prising the following seven items: soft skin and velvety, flat
feet, large/prominent ears, family history of ID, plantar
crease, autistic-like behavior, and macroorchidism. We con-
sidered the attribution to be of value 2 if soft skin and vel-
vety, flat feet, and large ears are present and 0 if absent. If
family history of ID, plantar crease, autistic-like behavior,
and macroorchidism are present, we considered the attribu-
tion to be of value 1 and 0 if absent. The maximum score is
10 points for postpubertal male subjects and nine for prepu-
bertal males or female subjects. Patients with score higher
than 5 have a significant yield of FXS and thus should be
considered for molecular testing to rule out the presence of
the Fragile X mutation. This combination of behaviors, fam-
ily history of ID/ASD, and physical manifestations in the
clinical checklist yield a high percentage of subjects with
FXS regardless their age, gender, or ethnic background.
For screening programs, we need to have a clinical
checklist with 100% sensitivity and the highest possible
specificity. Specificity and sensibility of our checklist could
not be assessed due to the method of our study. This is the
main limitation of our study.
Further validation studies should be undertaken in popu-
lations of different ethnic backgrounds to analyze the
scores obtained for patients with and without the Fragile X
gene mutation, based on the seven items considered to be
more discriminant for FXS in the present meta-analysis.
5 | CONCLUSION
In general, it is important for all physicians to carry out
Fragile X DNA testing for those with ID or ASD and to
carry out cascade testing in families where the Fragile X
mutation has been identified. In countries where such test-
ing is difficult to obtain, then the testing of those at highest
risk for FXS is worthwhile, and this study has identified the
highest risk features for patients with FXS that have been
used to design a simplified universal clinical checklist.
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